GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MediciNova Inc (NAS:MNOV) » Definitions » Interest Coverage

MediciNova (MediciNova) Interest Coverage : No Debt (1) (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is MediciNova Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. MediciNova's Operating Income for the three months ended in Dec. 2023 was $-2.49 Mil. MediciNova's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. MediciNova has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. MediciNova Inc has enough cash to cover all of its debt. Its financial situation is stable.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for MediciNova's Interest Coverage or its related term are showing as below:


MNOV's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 143.98
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


MediciNova Interest Coverage Historical Data

The historical data trend for MediciNova's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

MediciNova Interest Coverage Chart

MediciNova Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only No Debt No Debt No Debt No Debt No Debt

MediciNova Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt N/A N/A N/A No Debt

Competitive Comparison of MediciNova's Interest Coverage

For the Biotechnology subindustry, MediciNova's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MediciNova's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MediciNova's Interest Coverage distribution charts can be found below:

* The bar in red indicates where MediciNova's Interest Coverage falls into.



MediciNova Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

MediciNova's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, MediciNova's Interest Expense was $0.00 Mil. Its Operating Income was $-9.90 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

MediciNova had no debt (1).

MediciNova's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, MediciNova's Interest Expense was $0.00 Mil. Its Operating Income was $-2.49 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

MediciNova had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


MediciNova  (NAS:MNOV) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


MediciNova Interest Coverage Related Terms

Thank you for viewing the detailed overview of MediciNova's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


MediciNova (MediciNova) Business Description

Traded in Other Exchanges
Address
4275 Executive Square, Suite 300, La Jolla, CA, USA, 92037
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
Executives
Nicole Lemerond director 3 MURRAY HILL ROAD, SCARSDALE NY 10583
Hideki Nagao director 4350 LA JOLLA VILLAGE DRIVE, SUITE 950, SAN DIEGO CA 92122
Jason J Kruger officer: Chief Financial Officer 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Douglas Paulin officer: Chief Financial Officer 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Gaeta Federico C.a. officer: Chief Scientific Officer 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
3d Investment Partners Pte. Ltd. 10 percent owner 250 NORTH BRIDGE ROAD, #13-01 RAFFLES CITY TOWER, SINGAPORE U0 179101
3d Opportunity Master Fund 10 percent owner C/O MAPLES CORPORATE SERVICES LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Carolyn Beaver director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Stepanow Edward C Jr. officer: Chief Financial Officer 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA 92037
Kazuko Matsuda officer: Chief Medical Officer C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Yuichi Iwaki director C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Carla Reyes officer: Chief Financial Officer 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Yoshio Ishizaka director 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Yutaka Kobayashi director 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Geoffrey Obrien officer: Vice President 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037

MediciNova (MediciNova) Headlines

From GuruFocus